SNN
Smith & Nephew SNATS Inc
NYSE: SNN · HEALTHCARE · MEDICAL DEVICES
$30.05
-0.78% today
Updated 2026-06-05
Market cap
$13.29B
P/E ratio
21.90
P/S ratio
2.16x
EPS (TTM)
$1.43
Dividend yield
2.50%
52W range
$28 – $38
Volume
1.2M
WallStSmart proprietary scores
60
out of 100
Grade: C+
Hold
Investment rating
7.3
Growth
B+7.0
Quality
B+6.5
Profitability
B5.7
Valuation
C+5/9
Piotroski F-Score
Moderate
2.5
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$34.99
+16.44%
12-Month target
$32.39
+7.79%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $594.67M — positive
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $5.21B | $5.55B | $5.81B | $6.18B | $6.16B |
| Net income | $223.00M | $263.00M | $412.00M | $626.46M | $330.82M |
| EPS | — | — | — | — | $1.43 |
| Free cash flow | $110.00M | $181.00M | $606.00M | $853.99M | $594.67M |
| Profit margin | 4.28% | 4.74% | 7.09% | 10.14% | 10.10% |
Peer comparison
Smart narrative
Smith & Nephew SNATS Inc trades at $30.05. representing a P/E of 21.90x trailing earnings. Our Smart Value Score of 60/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 2.52, it sits in the grey zone. TTM revenue stands at $6.16B. with profit margins at 10.10%.
Frequently asked questions
What is Smith & Nephew SNATS Inc's stock price?
Smith & Nephew SNATS Inc (SNN) trades at $30.05, on a P/E of 21.9x and a P/S of 2.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Smith & Nephew SNATS Inc overvalued?
Smith & Nephew SNATS Inc carries a Smart Value Score of 60/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Smith & Nephew SNATS Inc (SNN)?
The 12-month analyst consensus target is $34.99, about 16.4% above the current $30.05. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Smith & Nephew SNATS Inc's revenue?
Smith & Nephew SNATS Inc's trailing twelve-month revenue is $6.16B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Smith & Nephew SNATS Inc's Altman Z-Score is 2.52, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.16x
ROE19.63%
Beta0.67
50D MA$31.35
200D MA$33.89
Shares out0.42B
Float2.10B
Short ratio—
Avg volume1.2M
Performance
1 week+0.00%
1 month+3.62%
3 months-6.09%
YTD-6.71%
1 year—
3 years—
5 years—